Revolving door policy

GSK
GSK has introduced a revolving door policy to mitigate the risk of conflicts of interest for new employees recruited directly from the public sector.
Continue reading

Possible partnership

Merck & Co
Merck & Co., Inc. partnered with non-government organisation (NGO) Possible to strengthen supply chains in Nepal.
Continue reading

Financial, Environmental and Social Profit and Loss capturing approach

Novartis
The Financial, Environmental and Social Profit and Loss (FES P&L) approach aims to measure the social and economic impact of Novartis’ social activities on local communities.
Continue reading

Coupon/Loyalty Programme

Boehringer Ingelheim
Boehringer Ingelheim is piloting the Coupon/Loyalty Programme, which targets both patients and healthcare professionals by providing points, based on patients’ healthy behaviour.
Continue reading

PreCare

Boehringer Ingelheim
PreCare is a new business model aiming to reach low-income communities in Kenya.
Continue reading

M-Tiba mobile wallet

Pfizer
Pfizer has supported the development and implementation of M-Tiba, a mobile wallet for healthcare savings and payments.
Continue reading
Regional Business Partner Compliance Pocket Guide

Regional Business Partner Compliance Pocket Guide

Gilead
The Regional Business Partner Compliance Pocket Guide is a guide to support compliance by third parties working with Gilead.
Continue reading
MVacciNation

mVacciNation

GSK
GSK’s mVacciNation programme is a mobile technology-based supply chain management capacity building programme, aiming to increase childhood immunisation in Mozambique.
Continue reading

New pricing policy based on an analysis of populations’ ability to pay in key out-of-pocket markets

AstraZeneca
AstraZeneca has a new pricing policy for its respiratory and cardiovascular disease products in certain key out-of-pocket markets in scope, based on an ability-to-pay analysis.
Continue reading

Healthy Heart Africa Global Advisory Board and National Steering Committee

AstraZeneca
AstraZeneca has developed an internal governance structure for its Healthy Heart Africa programme, consisting of a Global Advisory Board and National Steering Committee.
Continue reading

Global Established Products (GEP) portfolio

Pfizer
Pfizer established a governance structure to ensure a formal mechanism for strategy development, assessment and implementation regarding its established products portfolio.
Continue reading

Tuberculosis-focused capacity building

Eli Lilly
Eli Lilly is undertaking a range of capacity building projects in India focused on tuberculosis.
Continue reading
Lilly Expanding Access For People (LEAP)

Lilly Expanding Access for People (LEAP)

Eli Lilly
Lilly Expanding Access for People (LEAP) targets diabetes in the emerging middle class in China.
Continue reading
Community-based Hypertension Improvement Project

Community-based Hypertension Improvement Project

Novartis
The Community-based Hypertension Improvement Project (ComHIP) is testing an innovative healthcare model for hypertension in Ghana.
Continue reading

Benchmarking of targets, access initiatives in line with the Sustainable Development Goals

Merck KGaA, Novo Nordisk
Merck KGaA and Novo Nordisk are realigning their access-related targets and access initiatives with the Sustainable Development Goals (SDGs).
Continue reading

The Quick-Start initiative

Bristol-Myers Squibb
Bristol-Myers Squibb is involved in the launch of an innovative structured donation programme aimed at curing hepatitis C.
Continue reading

Malaria-focused capacity building

Novartis
Novartis is undertaking several capacity building projects focused on malaria in sub-Saharan Africa.
Continue reading
Young Health Programme

Young Health Programme

AstraZeneca
AstraZeneca’s Young Health Programme is a philanthropic capacity building programme focused on preventing non-communicable diseases among adolescents.
Continue reading

BAAF Distribution Optimisation project

Novo Nordisk
Novo Nordisk is working with distributors across different countries in Africa to optimise the supply chain and reduce the price to patients of its full diabetes portfolio.
Continue reading

International Society of Pharmacovigilance Special Interest Group

Bayer
Bayer co-founded an International Society of Pharmacovigilance Special Interest Group to develop and share innovative risk minimisation methods and tools.
Continue reading

StartHealth investment programme

Pfizer
Pfizer is supporting StartHealth, a health technology start-up investment programme.
Continue reading

Advisory board on climate change and health

Sanofi
Sanofi has established an advisory board to better understand the impact of climate change on health.
Continue reading

Hepatitis C virus elimination programme

Gilead
Gilead launched an innovative donation programme with the goal of eliminating hepatitis C virus in Georgia.
Continue reading

Non-exclusive voluntary licensing outside of HIV/AIDS

Bristol-Myers Squibb, Gilead
Gilead and Bristol-Myers Squibb take the first moves, from companies in scope of the Access to Medicine Index 2016, outside non-exclusive voluntary licensing in HIV/AIDS.
Continue reading

EASYDAY/EASYFOOD

Sanofi
EASYDAY/EASYFOOD aims to anticipate the risk of unethical behaviour in relation to events and dining expenses.
Continue reading
Leprosy-focused Capacity Building

Leprosy-focused capacity building

Novartis
Novartis is undertaking a range of projects to build local capacity to address leprosy, mainly in south-east Asia.
Continue reading
Su-Swastha

Su-Swastha

Merck KGaA
Su-Swastha is a commercially viable, socially responsible business model implemented in rural India.
Continue reading

Commitment to R&D for AMR

AstraZeneca, GSK, Johnson & Johnson, Merck & Co, Merck KGaA, Novartis, Pfizer, Roche, Sanofi
Nine companies have committed to R&D for antimicrobial resistance (AMR), signing the Davos Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance.
Continue reading

Novartis Access programme

Novartis
Novartis Access is a new company-wide business model that supports access to medicine in low- and lower-middle income countries.
Continue reading
Africa 2020 R&D Capacity Building

Africa 2020 R&D capacity building

GSK
GSK’s Africa 2020 strategy includes a range of R&D capacity building partnerships in sub-Saharan Africa.
Continue reading

Cities Changing Diabetes

Novo Nordisk
Cities Changing Diabetes is an innovative stakeholder engagement programme, aiming to identify and address the root causes of the rise of type 2 diabetes in urban areas.
Continue reading